Hello! Am I audible?
Hi, three questions from me. One, you know, this is with reference to, you know, onboarding Mr. Patel in North America. You know what really drove this decision and you know, considering that you've been in the market for almost two decades now, how are things likely to change with him coming on board?
Hi, a couple of questions from me. One, sir, if I look at your fixed cost base excluding R&D for FY25 versus FY24, there's been a quantum leap. And we're aware that it's because of plethora of reasons, Eugia remediation, Pen-G, Vizag, China, so on and so forth. I mean, just to get a sense, how much would that quantum be for FY25, these one-offs, because of regulatory reasons because of state considerations or because of just amplifying capacity, which is not contributing to revenue.
Okay. So, I mean, the one-offs like the Rs. 100 crore that you spoke of in Q4, and in Q1 and Q2, we are aware that P en-G and remediation was resulting in a significant expansion in cost space. So, I was just trying to get a sense on what that number is . Would that be to the tune of Rs. 400-500 crores for FY25 or would it be materially low?
Hi, good morning. One on the API business you spoke about pricing pressure. I mean, this pricing pressure is on account of domestic supply being more aggressive or is it because of imports or is it because of both?
Okay. Because a 16% decline is something, to the best of my knowledge, I've never seen in this business in the last multiple quarters.
Hi, good morning. Couple of questions, Sir. Both on US and Europe, if you could give us a sense on what's the portfolio coverage currently ? S pecifically in US , how does Lannett help it improve say quantitatively and what are the steps to improve ? And similarly in Europe, things get a little complicated in Europe because it's a confederation of many countries. So, if you could give a more granular insight on some of your major markets. That's on portfolio coverage. On cashflows, CapEx intensity of the business continues to be reasonably high despite reasonable amount of capacities which continue to be unutilized. H1, it's already at ₹1500 crores, so how should we really now Penicillin CapEx intensity for the business given a vast footprint of unutilized capacities? Thanks.
Sir, if I could just chip in. I mean, I understand that you've got north of 10% volume share but does it come after covering say 50% of the market or does it come after covering 60% of the market? It's really that's the metric that I was looking for.
Hi. Good morning. A couple of questions on Eugia and then on the US business. Over the last two years, how has your market share moved in the US injectables business? Because there has been quite a lot of movement in the marketplace. So, just wanted to get a pulse on how the market share has moved. And second, what is the dollar impact of revenue, say, in Q1 because of the remediation activity happening in Eugia-3?
Dollar impact revenue, because of Eugia-3.
Hi, good morning. Just a couple of questions on Eugia and Europe. On Eugia two questions. I mean, first, Sir, if we look at Eugia last quarter, which is Q1 of FY25 and Q4 of FY24, we were impacted anywhere by about US $15-$20 million on a quarterly basis because of Eugia -III. It was widely anticipated that this quarter much of that impact will be averted, so has that been averted to a large extent?
Okay, sure. So, would it, therefore, be safe to presume that the US $15-$20 million continues up until Q2 and then from Q3 onwards hopefully things should be all right?
Hi, good morning. Am I audible?
Okay. On Eugia Sir, you said that Eugia utilisation is currently at about 50% for Eugia-3, does this also include the expanded capacity of Eugia-3?
Hi, good morning. Couple of questions. Starting on Europe, if I were to adjust for the tax clawback, you're at about €206 million. How should we look at this business going forward here? Is this €200 million the new base for this business? and, in your response to an earlier participant, you commented you gave a metric, you said 30% of those 200 odd products. If you could elaborate in terms of what that 30% was?
Sure. Thank you. On the ROW markets, if you could elaborate and I mean there's been a solid growth about 25% odd in INR terms in this business, any specific markets which are driving them, is it one off or the Rs. 600 crore or Rs. 625 crore quarterly run rate is something that we should work with moving on?